Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Recap by typeshit. Full story at Times Now.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
Researchers at the American Academy of Ophthalmology meeting found NAION patients on GLP-1 drugs tended to develop it in the other eye sooner.
MedPage Today
A mental health news roundup points to a New York Times report that patients with eating disorders have little protection as GLP-1 use grows.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
Loading…